Compare Natera Inc. Common Stock (NTRA) vs Teck Resources (TECK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Teck Resources — how do they compare? Natera Inc. Common Stock trades at $393.27 (market cap $57.03B), while Teck Resources trades at $63.46 (market cap $32.79B). The key difference: Natera Inc. Common Stock is the larger of the two by market cap, and Teck Resources pays a 0.53% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Teck Resources for 15 Days on average.
| NTRA | TECK | |
|---|---|---|
Market Cap | $57.03B | $32.79B |
Volume | 1,131,157 | 1,600,168 |
Sector | Health | Basic Materials |
52-Week High | $425.64 | $71.97 |
52-Week Low | $179.42 | $38.23 |
Typical Hold Time | 0 Days | 15 Days |
Enterprise Value | $56.18B | $35.41B |
Dividend Yield | — | 0.53% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
TECK trades at $67.17, down 0.55% today, with a bullish technical signal from moving averages and strong earnings beats in recent quarters. Revenue and net income are projected to grow significantly in 2026, supported by a 17.85% net margin. Analyst consensus is strongly bullish, with 69% buy ratings, amid positive news flow including inclusion in Forbes' top companies for women and copper price optimism.
Outlook remains positive given earnings momentum and copper demand tailwinds, but risks include commodity price volatility and execution of the Anglo American merger. Cash flow turned positive in 2026 forecasts, though 2025 saw a net outflow. The stock offers value with a P/E of 18.82 and EV/EBITDA of 7.77, but investors should monitor merger progress and global economic conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Teck Resources
Teck Resources is a mining company focused on producing metals and minerals, including copper and zinc. Its operations supply materials used in infrastructure, manufacturing, and energy-related industries.
Read more on TECK →
